Global Cause
In this issue
-
It is essential to focus on preventing infections to tackle AMR
We are living through a global pandemic, with 5 million deaths associated with COVID since the start of 2020. However, the threat of antimicrobial resistance (AMR) continues to loom. The Global AMR Review Study highlighted that 700,000 people die of antimicrobial resistant infections each year and that without urgent action, the death toll could rise...
-
s Sponsored
Power to the people in AMR labs worldwide
The genomic sequencing revolution is enabling researchers in low and middle income countries to swiftly tackle challenges from AMR to COVID-19 as they emerge. AMR threatens healthcare at every level in every country. Partnerships are essential to enhance strategic surveillance in key countries worldwide. Our partners are equipped with genome sequencing and analytic expertise to...
-
s Sponsored
Joining forces against AMR: A ‘Manhattan Project’ for good
COVID-19 has highlighted how vulnerable we still are to infectious diseases. Antimicrobial resistance, often dubbed the “silent pandemic”, threatens to undermine the efficacy of common antibiotics, the foundation of modern healthcare. The history of medicine, says Dr Dominic De Souza, Global Head Anti-Infectives Sustainability and AMR Program at Sandoz, can be divided effectively into two...
-
s Sponsored
Facilitating scientific collaboration to accelerate antibiotic discovery
An antibiotic data-sharing platform is helping scientists around the globe tackle the ongoing threat of AMR. Antibiotic resistance is a dire and growing public health threat, with the United Nations projecting that by 2050 drug-resistant diseases could cause 10 million deaths globally each year. New antibiotics are urgently needed to protect patients from antibiotic-resistant “superbugs,”...
-
Global not-for-profit partnerships must be part of drug resistance solution
COVID-19 has made it clear our health and wellbeing are inextricably linked regardless of where we live. It has also demonstrated that unlocking global cooperation and investment cannot wait for a threat to emerge. Unlike the novel coronavirus, which required bold, reactive efforts to identify medical countermeasures, there are too few promising solutions in the...
-
The vital role of nurses and midwives in the management of AMR
The World Health Organization is calling for investment in the health workforce to ensure patients receive safe and high-quality evidence-based care. Nurses and midwives in health care settings around the world are responsible for the safe administration of medicines to patients. They are also responsible for monitoring patients’ wellbeing, vital signs and changes in clinical...
-
Tackling AMR through addressing sociocultural inequities
For sustained improvement in antibiotic prescribing we need to understand the factors that influence their usage. The relationship that we have developed with antibiotics is complex and driven by many factors beyond health and disease. We have long considered antibiotics to be miracle drugs due to their ability to treat diseases, however, their overuse is...
-
The imminent threat of AMR and why we must prepare
AMR is a silent pandemic that needs attention now. Globally, we need to take action or it will continue to claim lives. It’s been 18 months since the world was struck by the COVID-19 pandemic. Though vaccines and treatments were developed in less than a year, politicians and experts will meet at a special World...
-
The last chance to reinvigorate AMR innovation
The needs of small and medium-sized enterprises (SMEs) must be considered when reshaping the regulatory framework intended to incentivise AMR innovation. SMEs are keen to contribute to a dialogue with policymakers. As we painfully enter a post COVID era, Europe is organising itself to ensure that it is not caught unawares in the event of a new pandemic....
-
s Sponsored
New strategies for clinical trials are needed to combat AMR
The continued threat of antimicrobial drug resistance (AMR) spawns a wide spectrum of anti-infective strategies. Dr Daniel Sahm, who has worked in drug development for 30 years and is Chief Scientific Officer at IHMA, states that small molecule drugs developed for infectious diseases are not maintaining the level of effectiveness needed to keep up with...